CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
ranibizumab, dexamethasone and verteporfin +1 moredrug
Likely dose
ranibizumab, dexamethasone and verteporfin 500 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00390208
NCT00390208Phase 2Completed
CompareCT.gov

A Prospective Masked Pilot Study Comparing Group 1 Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Group 2 Monotherapy - Intravitreal Ranibizumab Alone.

Bay Area Retina Associates·interventional·Posted Oct 19, 2006·Updated May 27, 2010

In Brief

A Phase 2 clinical trial evaluating ranibizumab, dexamethasone and verteporfin and Ranibizumab for Age Related Macular Degeneration. Completed, enrolled 60 participants across 4 sites.

Detailed Summary

The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of Age-Related Macular Degeneration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Related Macular Degeneration
CountriesUnited States
CollaboratorsQLT Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 19, 2006
Enrollment StartAug 1, 2006
Primary CompletionDec 1, 2008
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.7 years ago

Interventions

ranibizumab, dexamethasone and verteporfindrug

One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.

Ranibizumabdrug

One 0.5 mg intravitreal Ranibizumab injection